JAIDS Journal of Acquired Immune Deficiency Syndromes:
Characterization of Nevirapine Resistance Mutations in Women With Subtype A Vs. D HIV-1 6–8 Weeks After Single-Dose Nevirapine (HIVNET 012)
Eshleman, Susan H. MD, PhD*; Guay, Laura A. MD*; Mwatha, Anthony MS†; Brown, Elizabeth R. ScD‡; Cunningham, Shawn P. MT(ASCP)*; Musoke, Philippa MBChB§; Mmiro, Francis MBChB-FRCOG¶; Jackson, J. Brooks MBA, MD*
From *Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD; †Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA; ‡Department of Biostatistics, University of Washington, Seattle; and §Departments of Paediatrics and ¶Obstetrics and Gynaecology, Makerere University, Kampala, Uganda.
Received for publication July 14, 2003; accepted October 28, 2003.
This work was supported by (1) the HIV Network for Prevention Trials (HIVNET) and the US National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Dept. of Health and Human Services (DHHS), through contract N01-AI-35173 with Family Health International, contract N01-AI-45200 with Fred Hutchinson Cancer Research Center, and subcontracts with Johns Hopkins University and Makerere University (NOI-AI-35173-417); (2) the HIV Prevention Trials Network (HPTN) sponsored by the NIAID, National Institutes of Child Health and Human Development (NICH/HD), National Institute on Drug Abuse, National Institute of Mental Health, and Office of AIDS Research, of the NIH, DHHS (U01-AI-46745 and U01-AI-48054); (3) the Adult AIDS Clinical Trials Groups (NIH, Division of AIDS, NIAID); and (4) R01-HD-42965-01.
Dr. Jackson and Dr. Guay have received honoraria and travel expenses for invited talks partially sponsored by Boehringer Ingelheim. Dr. Eshleman has received research support from Applied Biosystems (former manufacturer of the ViroSeq kits) and Celera Diagnostics (current manufacturer of the ViroSeq kits). She has also received honoria and travel expenses from Abbott Laboratories (distributor of the ViroSeq kits) for talks related to HIV genotyping.
Reprints: Susan Eshleman, Department of Pathology, The Johns Hopkins Medical Institutions, Ross Bldg. 646, 720 Rutland Ave., Baltimore, MD 21205 (e-mail: firstname.lastname@example.org).
Objective: To compare the number and type of nevirapine (NVP) resistance mutations detected in Ugandan women with subtype A vs. D HIV-1 infection after single-dose NVP prophylaxis.
Design: In the HIVNET 012 trial, a higher rate of NVP resistance (NVPR) was seen in women with subtype D than A after single-dose NVP. In this study, the number and type of NVPR mutations detected 6–8 weeks after NVP were compared in women with subtypes A vs. D.
Methods: Plasma samples were available for 282 (92%) of 306 women who received NVP in HIVNET 012. Samples were analyzed with the ViroSeq HIV-1 Genotyping System (Applied Biosystems, Foster City, CA). Subtyping was performed by phylogenetic analysis of pol region sequences.
Results: Results were obtained for 279 women, including 147 with subtype A, 98 with subtype D, 6 with subtype C, and 28 with recombinant HIV-1. NVPR mutations were detected in 70 (25%) of 279 women. NVPR was more common in women with subtype D vs. A (35.7 vs. 19%, P = 0.0035). Complex patterns of NVPR mutations were detected in both subtypes. Among women with NVPR, 43% of women with subtype A and 46% of women with subtype D had ≥2 NVPR mutations. The mean number and pattern of NVPR mutations detected in women with subtypes A and D were similar.
Conclusions: This study confirms a higher rate of NVPR in women with subtype D than A and further defines the pattern of NVPR mutations that emerge 6–8 weeks after single-dose NVP prophylaxis in these subtypes.
Nevirapine (NVP) is a potent inhibitor of HIV-1 reverse transcriptase (RT). The HIVNET 012 trial tested the efficacy of a single-dose regimen of NVP for prevention of HIV-1 mother-to-child transmission (MTCT). Pregnant women received a single 200-mg NVP dose at the onset of labor, and their infants received a single 2-mg/kg dose within 72 hours of birth. That regimen was shown to be more effective than a short course of zidovudine prophylaxis starting in labor and was simpler and much less expensive. 1–3 The HIVNET 012 regimen is now being implemented in resource-poor countries around the world.
In a previous study, we analyzed NVP resistance (NVPR) in a subset of the women in the NVP arm of HIVNET 012. HIV-1 variants with NVPR mutations were detected in 21 (19%) of 111 women by HIV-1 genotyping (population sequencing) 6–8 weeks after NVP administration. 4 NVPR mutations were no longer detectable in women 12–24 months after delivery. In an exploratory study that included 102 of the 111 women described here (excluding the 9 women whose infants were infected after 6–8 weeks), we found a higher rate of NVPR among women with subtype D than subtype A. 5 The association between HIV-1 subtype and emergence of NVPR did not appear to reflect a difference in the stage of disease among women with subtype A vs. D, since the baseline viral loads and baseline CD4 cell counts were similar in the 2 groups. 5 The potential for HIV-1 subtype to influence the rate of NVPR after NVP prophylaxis suggests that the rate of NVPR in women receiving the HIVNET 012 regimen may vary from region to region depending on which subtypes are prevalent.
Recent studies have shown that HIV-1 subtype may influence the pattern of resistance mutations that emerge after exposure to antiretroviral drugs. 6,7 Subtype-specific differences in protease and RT sequences may influence the rate at which a specific mutation emerges 8 and the type of amino acid selected at a given position under drug pressure. 9,10 Differences in sequences of nonsubtype B viruses may also lead to emergence of novel subtype-specific drug resistance mutations at positions not associated with drug resistance in subtype B. 11 A detailed comparison of the number and type of NVPR mutations selected by the single-dose regimen in women with subtype A vs. D was not possible in the exploratory study described above, because the subset of 102 women included only 6 women with subtype A and 10 women with subtype D who had NVPR mutations detected at the 6- to 8-week time point. 5 By expanding analysis of NVPR in the HIVNET 012 cohort to include all available 6- to 8-week samples from women who received NVP prophylaxis (282 women), we are able to define further the relationship between subtype and emergence of NVPR and to compare the number and type of NVPR mutations that emerge in women with subtype A vs. D after NVP prophylaxis.
MATERIALS AND METHODS
Study Visits and Results From HIVNET 012
The HIVNET 012 study protocol was reviewed and approved by institutional review boards in Uganda and the United States, and informed consent was obtained from all women before enrollment. Women were antiretroviral drug naive before NVP administration and did not receive antiretroviral therapy after the single dose of NVP, consistent with the standard of care in Uganda. Detailed methods and results of HIVNET 012 are presented elsewhere, 1–3 including methods for determining baseline HIV-1 RNA levels and baseline CD4 cell counts. Plasma samples collected 6–8 weeks after delivery were used for analysis of NVPR mutations and for HIV-1 subtyping.
HIV-1 genotyping was performed using the Applied Biosystems ViroSeq HIV-1 Genotyping System (Applied Biosystems, Foster City, CA), as described previously. 4,5 HIV-1 genotyping was considered to be successful if a sequence corresponding to protease amino acids 1–99 and RT amino acids 1–324 (297 and 972 nucleotides, respectively) was obtained. Genotypes were analyzed only if bidirectional sequence data (sense and antisense) were obtained at all positions in RT associated with NVPR. HIV-1 sequences from each woman were examined for the presence of mutations associated with NVPR (A98G, L100I, K101E, K103N, V106A, V108I, V179D Y181C/I, Y188C/H/L, G190A/S, M230L), including accessory mutations (K101Q, V106I, P225H, Y318F) and mutations associated with hypersusceptibility to NVP (P236L) [IAS-USA Drug Resistance Mutations Group (2002), Stanford HIV RT and Protease Sequence Database (http://hivdb.stanford.edu/cgi-bin/NNRTIResiNote.cgi)].
Phylogenetic Analysis of HIV-1 Subtypes
Subtyping was performed using contiguous nucleotide sequences corresponding to protease amino acids 1–99 and RT amino acids 1–324. Sequences were examined for evidence of intersubtype recombination using the Recombinant Identification Program 12 (available at http://hiv-web.lanl.gov/RIP/RIPsubmit.html) using a window size of 400 nucleotides. Reference sequences of known subtype were obtained from the HIV Sequence Database at the Los Alamos National Laboratory. 13 A detailed analysis of 13 of the 28 intersubtype recombinant sequences is presented elsewhere. 14
Sequences without evidence of intersubtype recombination were aligned using the biosequence editor Seqapp v1.9a169 (http://iubio.bio.indiana.edu/soft/molbio/seqapp/). Alignments included reference sequences recommended by the Los Alamos National Laboratory for HIV-1 subtype analysis. Phylogenetic analysis of HIV-1 subtypes was performed using PHYLIP v. 3.572 (available at http://evolution.genetics.washington.edu/phylip.html). Alignments were performed manually and did not require gap stripping. Distances between the sequences were calculated with DNADist, utilizing the Kimura-2 parameter as an optimal substitution model and a transition-transversion ratio of 1.5. Neighbor-Joining and Consense were used to create phylogenetic trees with 500 bootstrap replications (SeqBoot). Consensus trees were displayed with TreeView. 15 Bootstrap values >80 were considered acceptable for subtype assignment.
Logistic regression was used to evaluate correlates of maternal NVPR, including baseline viral load, baseline CD4 cell count, and HIV-1 subtype. All statistical analyses were done with SAS (version 8.1, SAS Institute, Cary, NC).
GenBank Accession Numbers
Sequences analyzed in this report included 110 sequences described previously 4,5 (GenBank accession numbers: AF388065–AF388098, AF388100–AF388166) and AY425349–AY425357, and 169 additional sequences AY435220–AY435388.
In HIVNET 012, 313 women were enrolled in the NVP arm and 306 received single-dose NVP at the onset of labor. Plasma samples collected 6–8 weeks after NVP (6–8 weeks after delivery) were available for 282 (92%) of those 306 women. All available plasma samples were analyzed with the Applied Biosystems ViroSeq HIV-1 Genotyping System. Genotyping analysis was successful for 279 (98.6%) of the 282 samples tested.
Analysis of HIV-1 Subtypes
HIV-1 subtyping of the pol (protease and RT) region was performed by phylogenetic methods. Intersubtype recombination in the pol region is common in Uganda. 14 Therefore, sequences were first analyzed for evidence of intersubtype recombination using the Recombinant Identification Program. HIV-1 sequences from 28 (10%) of the 279 women had evidence of intersubtype recombination. Unique patterns of recombination were observed in different women. The patterns of recombination observed in samples from 13 of those women are described in detail elsewhere. 14 There was clear evidence of intersubtype recombination within the RT region for 19 of the 28 women. RT sequences from the other 9 women appeared to be predominantly 1 subtype (7D, 1A, and 1C), with a second subtype in the protease/RT cleavage region and the N-terminus of the RT protein. The remaining 251 sequences, which showed no evidence of intersubtype recombination, were subtyped using phylogenetic methods described here. These methods identified 147 women with subtype A, 98 women with subtype D, and 6 women with subtype C infection.
Analysis of NVPR
NVPR mutations were detected in 70 (25%) of the 279 women (Table 1). Detection of NVPR mutations was associated with a higher baseline (pre-NVP) viral load and lower baseline CD4 cell count (per increase of 1 log10 HIV RNA: odds ratio [OR] = 3.1 [95% CI: 1.8–5.1, P < 0.0001], per decrease of 100 cells: OR = 1.3 [95% CI: 1.1–1.5, P = 0.0055]). The rate of NVPR was higher among women with subtype D than A. NVPR mutations were detected in 35 (35.7%) of the 98 women with subtype D, but in only 28 (19.1%) of the 147 women with subtype A (OR = 2.4 [95% CI: 1.3–4.2, univariate analysis]). In a logistic regression model controlling for baseline RNA and baseline CD4 cell count, all variables in the model were independent predictors of resistance. Controlling for baseline HIV-1 RNA and baseline CD4 cell count, the OR for subtype was 2.5 (95% CI: 1.3–4.9). This difference did not appear to reflect more advanced disease among women with subtype D vs. A, because baseline viral loads and baseline CD4 cell counts were similar for the 2 groups (median baseline viral load for A vs. D: 4.3 vs. 4.5 log10 HIV-1 RNA copies/mL, P = 0.428,Wilcoxon test; median baseline CD4 cell count for A vs. D: 495 vs. 405 cells/μL, P = 0.099, Wilcoxon test). These results are consistent with findings of our earlier exploratory studies. 4,5 Data from subtype C and recombinant HIV-1 are shown for comparison (Table 1) but were too limited for meaningful statistical analysis.
Analysis of NVPR Mutations
Seven different NVPR mutations were detected in this cohort: K101E, K103N, V106A, V108I, Y181C, Y188C, and G190A (Table 2). K103N and Y181C were the most common NVPR mutations detected (Table 2), representing 53.2% and 23.4%, respectively, of the 111 mutations detected among 70 women with NVPR. Both K103N and Y181C were detected at higher rates in women with subtype D than A. K103N was detected in 28 (28.6%) of 98 women with subtype D but in only 25 (17.0%) of 147 women with subtype A (P = 0.0313). Y181C was detected in 16 (16.3%) of 98 women with subtype D but in only 8 (5.4%) of 147 women with subtype A (P = 0.005). Deletion of codon 69, which has been associated with NVPR, was not observed. Accessory mutations were detected in 2 women: K101Q was detected in 1 woman with subtype C who also had the K103N mutation; V106I was detected in 1 woman with subtype D who did not have other NVPR mutations detected. Two of the NVPR mutations detected, K101E and V108I, are associated with low-level NVPR. The K101E mutation was detected in 5 women. All 5 women also had the K103N mutation detected, and 4 of those women had a 3rd mutation detected as well (2 with Y181C, 1 with Y188C, and 1 with G190A). The V108I mutation was detected in only 1 woman who had no other NVPR mutations detected. NVPR mutations detected in women with subtype C and recombinant HIV-1 are shown for comparison (Table 2) but were too limited for meaningful statistical analysis.
Complex patterns of NVPR mutations were detected. The type and number of NVPR mutations detected were similar among women with subtype A vs. D. Twenty-nine (41%) of the 70 women with NVPR had ≥2 NVPR mutations. This included 18 women with 2 mutations, 10 women with 3 mutations, and 1 woman with 4 mutations. More than 1 NVPR mutation was detected in 12 of 28 (42%) of women with subtype A and 16 of 35 (46%) of women with subtype D. Among the women with NVPR mutations, the mean number of NVPR mutations per woman was similar for women with subtype A vs. D (1.57 vs. 1.66, respectively).
This report reveals that complex patterns of NVPR mutations are detected 6–8 weeks after single-dose NVP in some women. It is likely that these mutations were selected as a result of the NVP exposure, because NVPR mutations were not detected in samples from >80 women enrolled in HIVNET 012 prior to antiretroviral drug administration (data not shown). Higher rates of both K103N and Y181C were detected in women with subtype D vs. A. However, the pattern of NVPR mutations, the percentage of women with ≥2 NVPR mutations, and the mean number of NVPR mutations per woman (among women with NVPR) were similar among women with these 2 subtypes. It is not known whether novel, subtype-specific NVPR mutations (other than those defined in subtype B) are selected in 1 or both of these subtypes. Because HIV-1 genotyping was performed by population sequencing, it was not possible to determine whether detection of multiple NVPR mutations in a sample represented selection of individual HIV-1 viruses with multiple, genetically linked mutations, or selection of different subpopulations of HIV-1 variants with different NVPR mutations. Further studies are needed to address that issue.
Data presented in this report further define the rate of NVPR following single-dose NVP prophylaxis. In a previous report, we found NVPR in 21 (19%) of 111 women who received NVP in HIVNET 012. 4 That study included a subset of the HIVNET 012 cohort, including 32 of 36 women whose infants were HIV-1 infected by 6–8 weeks of age (all available samples), 9 of 12 women whose infants were infected after 6–8 weeks (all available samples), and a randomly selected group of 70 women whose infants were not infected. That study, which was designed to include all women with infected infants, included a higher percentage of women with infected infants than the cohort of all women in the NVP arm of HIVNET 012 (28.8% vs. 11.5%, respectively). In HIVNET 012, women with infected infants tended to have higher baseline viral loads than women with uninfected infants. Because emergence of NVPR in HIVNET 012 was associated with higher baseline viral loads and lower baseline CD4 cell counts, 4 we speculated that the exploratory study may have overestimated the rate of NVPR across the entire cohort of women who received NVP in the HIVNET 012 trial. In contrast, the present expanded study (including all available samples) found a slightly higher rate of NVPR than the previous smaller study, with NVPR detected in 70 (25%) of 279 women. We do note, however, that the actual rate of NVPR in the entire cohort of 306 women who received NVP in HIVNET 012 may be slightly higher or lower, because genotyping results could only be obtained for 279 (91%) of those women.
Selection of NVP-resistant HIV-1 following single-dose prophylaxis is not unexpected, given the long-half life of NVP. HIV-1 variants with NVPR mutations are likely to be present as minority viral variants in HIV-1–infected patients before NVP exposure. 16,17 Rapid inhibition of the replication of NVP-sensitive virus would permit selection of NVPR variants. Indeed, NVPR variants were detectable in women in HIVNET 012 only 7 days after single-dose NVP, 18,19 and in women in HIVNET 023 only 2 weeks after administration of the same single-dose regimen. 20
This expanded study confirms our earlier finding, that a high baseline viral load and low baseline CD4 cell count are associated with emergence of NVPR in this setting. Because women in HIVNET 012 had relatively advanced HIV-1 disease, they may have been more likely to develop NVPR than women in other cohorts. In other settings, use of highly active antiretroviral therapy during pregnancy may reduce the rate of NVPR following single-dose NVP administration. However, results from PACTG 316 demonstrate that NVPR mutations can emerge after single-dose NVP in women receiving concurrent therapy with at least 1 other antiretroviral drug. 21
This extended study confirms that the rate of NVPR following single-dose NVP is higher for women with subtype D compared with subtype A. This suggests that the rate of NVPR following administration of the HIVNET 012 NVP regimen may vary from region to region, depending on which subtypes are prevalent. Further studies are needed to compare resistance rates in women with different subtypes and to test whether the fading of NVPR variants over time is influenced by HIV-1 subtype. It is not known whether emergence of NVPR after single-dose NVP prophylaxis will affect the efficacy of NVP prophylaxis in subsequent pregnancies or limit use of NVP or other nonnucleoside RT inhibitors (NNRTIs) for subsequent treatment of HIV-1 infection. The HIVNET 012 regimen can significantly reduce HIV-1 transmission in settings where other regimens are impractical and where treatment options are limited. The emergence of drug resistance with simplified perinatal prophylaxis regimens must be balanced against the need for simple and affordable interventions to prevent HIV-1 transmission in resource-poor settings.
We acknowledge the assistance of Melissa Allen (protocol specialist, Family Health International) and thank Estelle Piwowar-Manning, Constance Ducar, and the laboratory staff in Uganda for assistance with sample processing. The authors thank Eric Shulse and the HIV Genotyping Team at Celera Diagnostics for helpful discussions and for providing reagents used in this study.
1. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-infant transmission of HIV-1 in Kampala, Uganda: HIVNET-012 randomised trial. Lancet. 1999; 354:795–802.
2. Owor M, Deseyve M, Duefield C, et al. The one year safety and efficacy data of the HIVNET 012 trial. Paper presented at: XIII International AIDS Conference; July 9–14, 2002; Durban, South Africa.
3. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 months follow-up of the HIVNET 012 randomised trial. Lancet. 2003; 362:859–868.
4. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001; 15:1951–1957.
5. Eshleman SH, Becker-Pergola G, Deseyve M, et al. Impact of HIV-1 subtype on women receiving single dose NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET 012). J Infect Dis. 2001; 184:914–917.
6. Kantor R, Katzenstein D, Camacho R, et al. Genotypic analyses of RT and protease sequences from persons infected with non-subtype B HIV-1. Paper presented at: 10th Conference on Retroviruses and Opportunistic Infections, Feb 12–14, 2003; Boston, MA.
7. Caride E, Hertogs K, Larder B, et al. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Genes. 2001; 23:193–202.
8. Tanuri A, Soares MA, Dumans AT, et al. Synonymous genetic changes within subtype F may influence mutational routes to drug resistance. Antivir Ther. 2003; 8:S142.
9. Kantor R, Carvalho AP, Wynhoven B, et al. Nucleic acid differences between HIV-1 non-B and B reverse transcriptase and protease sequences at drug resistance positions. Antivir Ther. 2003; 8:S58.
10. Turner D, Brenner B, Spira B, et al. Novel drug resistance profiles in non-B subtype HIV-1 infections. Paper presented at: 10th Conference on Retroviruses and Opportunistic Infections; Feb 12–14, 2003; Boston, MA.
11. Abecasis A, Gomes P, Derdelinckx I, et al. L89I/V: a novel mutation selected by protease inhibitor therapy in subtype G, but not in subtype B-infected patients. Antivir Ther. 2003; 8:S140.
12. Siepel AC, Halpern AL, Macken C, et al. A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences. AIDS Res Hum Retroviruses. 1995; 11:1413–1416.
13. Shafer RW, Dupnik K, Winters MA, et al. A guide to HIV-1 reverse transcriptase and protease sequencing for drug resistance studies. Human Retroviruses and AIDS 2001: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences.
Available at: http://hiv-web.lanl.gov/
. Los Alamos, NM: Los Alamos National Laboratory; 2001. (accessed 12/03).
14. Eshleman SH, Gonzales MJ, Becker-Pergola G, et al. Identification of Ugandan HIV-1 variants with unique patterns of recombination in pol
involving subtypes A and D. AIDS Res Hum Retroviruses. 2002; 18:507–511.
15. Page RD. TreeView: an application to display phylogenetic trees on personal computers. Comput Appl Biosci. 1996; 12:357–358.
16. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA. 1998; 279:1984–1991.
17. Havlir DV, Eastman S, Gamst A, et al. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol. 1996; 70:7894–7899.
18. Eshleman SH, Jones D, Guay L, et al. HIV-1 variants with diverse nevirapine resistance mutations emerge rapidly after single-dose nevirapine: HIVNET 012. Antivir Ther. 2003; 8:S86.
19. Eshleman SH, Guay LA, Mwatha A, et al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6–8 weeks after single dose NVP prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses. (in press).
20. Kantor R, Lee E, Johnston E, et al. Rapid flux in non-nucleoside reverse transcriptase mutations among subtype C HIV-1-infected women after single dose nevirapine. Antivir Ther. 2003; 8:S85.
21. Cunningham CK, Chaix M-L, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of Pediatric AIDS Clinical Trials Group Protocol 316. J Infect Dis. 2002; 186:181–188.
This article has been cited 59 time(s).
Clinical Infectious DiseasesGreater Suppression of Nevirapine Resistance With 21-vs 7-Day Antiretroviral Regimens After Intrapartum Single-Dose Nevirapine for Prevention of Mother-to-Child Transmission of HIVClinical Infectious Diseases
HIV/AIDS in Asia
New England Journal of Medicine
Antiretroviral agents - How best to protect infants from HIV and save their mothers from AIDS
New England Journal of Medicine, 351(3):
International Journal of Std & AIDSResistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in ChinaInternational Journal of Std & AIDS
HIV-1 Resistance to First- and Second-Generation Non-nucleoside Reverse Transcriptase Inhibitors
AIDS Reviews, 11(3):
AIDS Research and Human Retroviruses
Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine
AIDS Research and Human Retroviruses, 21(4):
AIDS Research and Human RetrovirusesPersistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancyAIDS Research and Human Retroviruses
AIDS Research and Human RetrovirusesA radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from UgandaAIDS Research and Human Retroviruses
Clinical Infectious DiseasesEfficacy and Safety of 1-Month Postpartum Zidovudine-Didanosine to Prevent HIV-Resistance Mutations after Intrapartum Single-Dose NevirapineClinical Infectious Diseases
Journal of Infectious DiseasesNevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmissionJournal of Infectious Diseases
Current HIV Research
The challenge of antiretroviral-drug-resistant HIV: Is there any possible clinical advantage?
Current HIV Research, 2(3):
Journal of Infectious Diseases
Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N Nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012
Journal of Infectious Diseases, 192(1):
First-line antiretroviral therapy in Africa - How evidence-based are our recommendations?
AIDS Reviews, 7(3):
Antimicrobial Agents and ChemotherapyImpact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected childrenAntimicrobial Agents and Chemotherapy
AIDS Research and Human Retroviruses
Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose NVP prophylaxis: HIVNET 012
AIDS Research and Human Retroviruses, 20(6):
M S-Medecine Sciences
HIV drug resistance and optimization of antiviral treatment in resource-poor countries
M S-Medecine Sciences, 20():
Journal of Infectious Diseases
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP
Journal of Infectious Diseases, 192(1):
Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns
Clinical Drug Investigation
Antiretroviral therapy for prevention of mother-to-child HIV transmission - Focus on single-dose nevirapine
Clinical Drug Investigation, 26():
AIDS Research and Human Retroviruses
HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D
AIDS Research and Human Retroviruses, 23(6):
Journal of Infectious DiseasesIdentification of Nevirapine-Resistant HIV-1 in the Latent Reservoir after Single-Dose Nevirapine to Prevent Mother-to-Child Transmission of HIV-1Journal of Infectious Diseases
Clinical Infectious DiseasesNevirapine Resistance by Timing of HIV Type 1 Infection in Infants Treated with Single-Dose NevirapineClinical Infectious Diseases
A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers
AIDS Research and Human Retroviruses
Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Cote d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission
AIDS Research and Human Retroviruses, 21():
AIDS Research and Human RetrovirusesComparison of Laboratory Methods for Analysis of Non-nucleoside Reverse Transcriptase Inhibitor Resistance in Ugandan InfantsAIDS Research and Human Retroviruses
Journal of Medicinal ChemistryStructure based activity prediction of HIV-1 reverse transcriptase inhibitorsJournal of Medicinal Chemistry
Journal of Clinical MicrobiologySensitive oligonucleotide Ligation assay for low-level detection of Nevirapine resistance mutations in human immunodeficiency virus type 1 quasispeciesJournal of Clinical Microbiology
Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine
International Journal of EpidemiologyPrevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysisInternational Journal of Epidemiology
Presse MedicaleThe challenges of preventing mother-to-child transmission of HIV in AfricaPresse Medicale
Bjog-An International Journal of Obstetrics and GynaecologyPreventing mother-to-child transmission of HIV: successes and challengesBjog-An International Journal of Obstetrics and Gynaecology
Journal of VirologyGenetic analysis of simian immunodeficiency virus expressed in milk and selectively transmitted through breastfeedingJournal of Virology
American Journal of Tropical Medicine and Hygiene
Impact of Maternal Human Immunodeficiency Virus Infection on Birth Outcomes and Infant Survival in Rural Mozambique
American Journal of Tropical Medicine and Hygiene, 80(5):
Clinical Infectious Diseases
Rolling out antiretrovirals in Africa: There are still challenges ahead
Clinical Infectious Diseases, 41(3):
Journal of Molecular DiagnosticsSensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and DJournal of Molecular Diagnostics
American Journal of Obstetrics and GynecologyInternational recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 updateAmerican Journal of Obstetrics and Gynecology
Reviews in Medical VirologyBiological mechanisms of vertical human immunodeficiency virus (HIV-1) transmissionReviews in Medical Virology
Journal of Infectious DiseasesAssociations between CYP2B6 Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African AmericansJournal of Infectious Diseases
Prevention of mother-to-child transmission of HIV - Successes, controversies and critical questions
AIDS Reviews, 6(3):
Journal of Clinical Pharmacy and Therapeutics
Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection
Journal of Clinical Pharmacy and Therapeutics, 32(3):
AIDS Research and Human RetrovirusesAnalysis of Drug Resistance in Children Receiving Antiretroviral Therapy for Treatment of HIV-1 Infection in UgandaAIDS Research and Human Retroviruses
Mother-to-child transmission of HIV-1: Advances and controversies of the twentieth centuries
AIDS Reviews, 6(2):
VirologieRole of NNRTIs in the prevention of HIV-1 mother to child transmissionVirologie
Anais Da Academia Brasileira De Ciencias
Overview of genotypic and clinical profiles of human immunodeficiency virus type 1-infected children in Rio de Janeiro, Brazil
Anais Da Academia Brasileira De Ciencias, 76(4):
Lancet Infectious Diseases
A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries
Lancet Infectious Diseases, 6(1):
The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa
Antiviral Therapy, 13(5):
LancetReduction of HIV-1 drug resistance after intrapartum single-dose nevirapineLancet
AIDS Research and Human Retroviruses
Phenotypic drug resistance patterns in subtype a HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations
AIDS Research and Human Retroviruses, 22(3):
Clinical Infectious DiseasesClinical Implications of HIV-1 Minority VariantsClinical Infectious Diseases
Current Opinion in Infectious DiseasesStrategies to prevent mother-to-child transmission of HIVCurrent Opinion in Infectious Diseases
JAIDS Journal of Acquired Immune Deficiency SyndromesQuantitative Analysis of HIV-1 Variants With the K103N Resistance Mutation After Single-Dose Nevirapine in Women With HIV-1 Subtypes A, C, and DJAIDS Journal of Acquired Immune Deficiency Syndromes
HIV-1; nevirapine; drug resistance; subtype; Uganda
© 2004 Lippincott Williams & Wilkins, Inc.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Highlight selected keywords in the article text.
Data is temporarily unavailable. Please try again soon.